✦ LIBER ✦

Does Acid Suppressive Therapy Reduce the Risk of Laryngeal Cancer Recurrence?

✍ Scribed by Mohammed A. Qadeer; Rocio Lopez; Benjamin G. Wood; Ramon Esclamado; Marshall Strome; Michael F. Vaezi

Book ID: 110087835
Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 293 KB
Volume: 115
Category: Article
ISSN: 0023-852X
DOI: 10.1097/01.mlg.0000177987.40090.e9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Does diabetes therapy influence the risk

Does diabetes therapy influence the risk of cancer?

✍ U. Smith; E. A. M. Gale 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 264 KB

Does gastric acid suppression increase t

Does gastric acid suppression increase the risk of drug allergies?

✍ C. Pickard; A. P. Sampson 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB

Perioperative blood transfusion does not

Perioperative blood transfusion does not increase the risk of colorectal cancer recurrence

✍ Paul L. Weiden; Michael A. Bean; Pat Schultz 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 413 KB 👁 2 views

An adverse relationship between perioperative blood transfusions and the risk of subsequent recurrence of cancer was reported recently. We reviewed retrospectively the records of 171 patients who received initial therapy for colorectal adenocarcinoma from 1977 to 1979 at the Virginia Mason Medical C

Does prophylactic hypervolemic therapy r

Does prophylactic hypervolemic therapy reduce the risk of symptomatic vasospasm after aneurysmal subarachnoid hemorrhage?

✍ Stephan A. Mayer 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 98 KB

Long-term risk of breast cancer recurren

Long-term risk of breast cancer recurrence: the need for extended adjuvant therapy

✍ Manfred Kaufmann; Achim Rody 📂 Article 📅 2005 🏛 Springer-Verlag 🌐 English ⚖ 312 KB

Does interferon therapy for chronic hepa

Does interferon therapy for chronic hepatitis B reduce the risks of developing cirrhosis and hepatocellular carcinoma?

✍ Anna S. F. Lok 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 413 KB

Objective: To estimate the cost-effectiveness of interferon-a2B for the treatment of patients with chronic hepatitis B infection who are positive for hepatitis B e antigen (HBeAg). Design: Meta-analysis of nine randomized controlled trials and cost-effectiveness analysis, projecting the clinical an